Granules India Annual General Meeting
Granules India convened its 35th AGM for August 06, 2026. Agenda includes adopting FY26 financials and approving a Rs.1.75 per share final dividend.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements with these filters
Granules India convened its 35th AGM for August 06, 2026. Agenda includes adopting FY26 financials and approving a Rs.1.75 per share final dividend.
Granules India Limited submitted its Integrated Annual Report for FY 2025-26. The 35th AGM is scheduled for August 06, 2026, via video conferencing.
Granules India Ltd will hold a board meeting on 21 July 2026 to approve its unaudited Q1 results. Insider trading window remains closed till 23 July 2026.
Granules India secured Sole First-to-File ANDA status for Sodium Oxybate Extended-Release. This milestone strengthens its complex generics portfolio in the US market.
Granules India reported Q3FY26 revenue of ₹13,879 Mn (up 22% YoY) and PAT of ₹1,502 Mn (up 28% YoY), driven by Finished Dosage growth in North America and Europe.
Granules India's US subsidiary received a USFDA EIR with VAI classification for its Chantilly facility. The report concludes a March 2026 inspection involving four observations.
Granules India reported Q3FY26 revenue of ₹13,879 Mn with a 22% YoY growth. Strategy focuses on shifting from integrated to complex generics, supported by R&D and US portfolio expansion.
Granules India clarified that recent trading volume spurts are purely market-driven. The company confirmed compliance with all SEBI price-sensitive disclosure requirements.